MetaCap

Aura Biosciences Inc. Company Profile

NASDAQ: AURAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

6.43-0.035 (-0.54%)

Market open · Delayed 15 min · as of Oct 8, 9:40 AM ET

Aura Biosciences at a glance

Aura Biosciences Inc. (NASDAQ: AURA) is a Biotechnology: Biological Products (No Diagnostic Substances) company in the Health Care sector headquartered in Boston, MA. Aura Biosciences is led by Ms. Natalie C. Holles and employs about 113 people. The company's shares have traded publicly since 2021.

At a market capitalization of $669.9 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001501796, which identifies the company's filings on EDGAR.

Summary generated from market data by MetaCap's automated system. Methodology

What does Aura Biosciences do?

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Business description based on the company's public filings.

Company information

Legal name
Aura Biosciences Inc.
Ticker
NASDAQ: AURA
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Ms. Natalie C. Holles
Employees
113
Headquarters
80 Guest Street, Boston, MA, United States
Phone
617 500 8864
IPO year
2021
Market cap
$669.93M
SEC CIK
0001501796

Companies similar to Aura Biosciences

AURA peer companies
CompanyPrice% ChgMarket capCompare
FDMT4D Molecular Therapeutics Inc.12.26-2.66%$677.02Mvs AURA
PRMEPrime Medicine Inc.3.77-3.30%$684.01Mvs AURA
SLDBSolid Biosciences Inc.6.69-2.33%$717.34Mvs AURA
PROKProKidney Corp. Class A1.55-1.27%$618.73Mvs AURA
DBVTDBV Technologies S.A. ADR9.74-0.36%$611.83Mvs AURA
DNAGinkgo Bioworks Holdings Inc. Class A10.90-4.93%$733.67Mvs AURA
CADLCandel Therapeutics Inc.9.62-2.03%$736.11Mvs AURA
ATTOAttovia Therapeutics Inc.16.20-1.34%$739.55Mvs AURA

Related